Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer. Issue 5 (16th January 2019)

• Record Type: Journal Article
• Authors: Kraaijenga, Sophie A.; Hamming‐Vrieze, Olga; Verheijen, Sonja; Lamers, Emmy; van der Molen, Lisette; Hilgers, Frans J.; van den Brekel, Michiel W.; Heemsbergen, Wilma D.
• Is Part Of: Head & neck. Volume 41:Issue 5(2019)
• Page Start: 1387
• Page End: 1394
• Publication Date: 2019-01-16
• Subjects: dose effect -- head and neck cancer -- NTCP -- radiotherapy -- trismus; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25573
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: We studied the relationship between trismus (maximum interincisor opening [MIO] ≤35 mm) and the dose to the ipsilateral masseter muscle (iMM) and ipsilateral medial pterygoid muscle (iMPM). Methods: Pretreatment and post‐treatment measurement of MIO at 13 weeks revealed 17% of trismus cases in 83 patients treated with chemoradiation and intensity‐modulated radiation therapy. Logistic regression models were fitted with dose parameters of the iMM and iMPM and baseline MIO (bMIO). A risk classification tree was generated to obtain optimal cut‐off values and risk groups. Results: Dose levels of iMM and iMPM were highly correlated due to proximity. Both iMPM and iMM dose parameters were predictive for trismus, especially mean dose and intermediate dose volume parameters. Adding bMIO, significantly improved Normal Tissue Complication Probability (NTCP) models. Optimal cutoffs were 58 Gy (mean dose iMPM), 22 Gy (mean dose iMM) and 46 mm (bMIO). Conclusions: Both iMPM and iMM doses, as well as bMIO, are clinically relevant parameters for trismus prediction.